登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《CID，4月27日，Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-04-27

  • Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

    Jiuxin Qu, Chi Wu, Xiaoyong Li, Guobin Zhang, Zhaofang Jiang, Xiaohe Li, Qing zhu, Lei Liu Author Notes

    Clinical Infectious Diseases, ciaa489, https://doi.org/10.1093/cid/ciaa489

    Published: 27 April 2020

    Abstract

    We profiled the serological responses to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein and spike (S) glycoprotein. The majority of the patients developed robust antibody responses between 17 and 23 days after illness onset. Delayed, but stronger antibody responses were observed in critical patients.

  • 原文来源：https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa489/5825506?searchresult=1
53浏览量
原文链接
相关报告

  • 《4月27日_SARS-CoV-2的IgG和IgM抗体概况》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-28
    • 1.时间：2020年4月27日 2.机构或团队：深圳市第三人民医院 3.事件概要： 深圳市第三人民医院多个科室的科研人员在Clinical Infectious Diseases期刊发表题为“Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)”的文章。 文章指出，研究人员概述了SARS-CoV-2核衣壳（N）蛋白和刺突（S）糖蛋白的血清学反应。大多数患者在发病后的17至23天之间出现了强烈的抗体反应，在重症患者中观察到延迟但更强的抗体反应。 4.附件： 原文链接：https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa489/5825506?searchresult=1
    127浏览量
    原文链接

  • 《Cell，4月2日，Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-05
    • Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses Shibo Jiang Christopher Hillyer Lanying Du Open AccessPublished:April 02, 2020DOI:https://doi.org/10.1016/j.it.2020.03.007 Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.
    121浏览量
    原文链接